Neumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory disease Advancing Neumifil into a Phase 2b clinical study due to start in 2024 St Andrews, UK – 1st June 2023 – Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis … Continue reading Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections